|
|||||
|
|
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors |
|
| Authors: | Dorota Kozielewicz Dorota Dybowska Kornelia Karwowska Magdalena Wietlicka-Piszcz |
| Affiliation: | 1. Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland;2. Department of Theoretical Foundations of Biomedical Sciences and Medical Computer Science, Faculty of Pharmacy, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland |
| Abstract: | Background: The incidence, course and risk factors associated with renal impairment (RI) in patients treated with triple therapy (TT) with pegylated interferon, ribavirin and telaprevir/boceprevir (PR/TVR/BOC) vs. dual therapy (DT) with PR were analyzed in this study. The association between RI and the decline of hemoglobin (Hb) was also examined. Methods: Retrospective analysis included 110 patients with genotype 1b chronic HCV infection, aged 18 – 80 years, who underwent TT (48TVR/14BOC) or DT (48 patients). The estimated glomerular filtration rate (eGFR), serum creatinine concentration (SCr) and Hb were measured at baseline, at weeks 4, 12, 24, 48 of treatment, and post-treatment week 24. Results: RI occurred in 9/62 (14.5%) patients who underwent TT, eight of whom were treated with TVR, one with BOC, and none treated with DT. The risk factors associated with RI were the following: TT (p = 0.0078), usage of nephrotoxic drugs (p = 0.0288), and older age (p < 0.0001). RI was reversible. A drop of Hb was associated with RI, older age and TT. Conclusions: RI is not a rare but a reversible complication of TT. It is necessary to monitor SCr and eGFR, especially in patients with a potential risk factor of RI occurrence. The Hb drop is more severe in patients with RI than in those without it. |
| Keywords: | boceprevir chronic hepatitis C renal impairment telaprevir |